Tirzepatide vials: what the label says

A question that comes up regularly in peptide communities: if there is 2.5 mg left in a tirzepatide vial and you want to inject 5 mg, can you draw out the remainder, inject it into a freshly reconstituted vial, and then draw the full 5 mg from that? The short answer is no, and this article explains why the prescribing information does not sanction that practice.

The question signals a real problem: dose-titration schedules do not always divide evenly into the volume a single-dose vial contains. But the solution the label describes is discarding unused drug, not pooling across containers^[1].

What the label says about Mounjaro and Zepbound vials

Both the Mounjaro (type-2 diabetes) and Zepbound (chronic weight management) prescribing information describe their glass vials as single-dose containers. The Mounjaro label, available via DailyMed, states verbatim in section 16.2: "Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F). If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days. Discard single-dose pen and single-dose vial after a total of 21 days at room temperature."^[1]

The Zepbound label reinforces the same point in its dosage-and-administration section, instructing patients to use a new syringe and needle for each injection and never mix tirzepatide with insulin^[2]. Neither label describes a procedure for combining residual drug from one container with the contents of another.

Why single-dose means discard, not pool

A single-dose vial is formulated without a preservative that would prevent microbial growth after the seal is breached. Multi-dose containers contain preservatives specifically because they are designed for repeated needle entry over a defined number of days. A single-dose vial, by contrast, offers no such protection. Once the stopper has been punctured, the risk profile changes.

Transferring drug from one opened single-dose vial into another vial introduces two separate contamination opportunities: the first needle-entry into the source vial, and the subsequent injection into the receiving vial. Neither event is covered by validated sterility claims, because the container was not designed for repeated access.

The pharmaceutical consequence is predictable. Any bacterial contamination introduced during the transfer is then injected subcutaneously with the dose. The problem does not show up immediately and may not show up at all in any given case, which is why the practice circulates in forums without obvious harm reports. That absence does not make it safe; it reflects the low baseline incidence of contamination events and the fact that most online users do not trace mild injection-site reactions to their source.

Multi-dose KwikPens: a different product

Eli Lilly also supplies tirzepatide in a single-patient-use multi-dose KwikPen format. The February 2026 FDA-approved four-dose KwikPen for Zepbound consolidates a full month of weekly injections in one device. That format is explicitly labelled for multiple uses by the same patient over 30 days or four doses, whichever comes first^[2]. The multi-dose pen carries its own titrated-dose mechanism and does not require drawing and transferring drug between containers.

If consistent dose delivery and reduced per-injection handling are the goal, the KwikPen format addresses that without requiring any vial-to-vial transfer. See the separate article on microdosing tirzepatide and multi-dose KwikPens for detail on what the label does and does not permit with the dial.

What about compounded tirzepatide vials

Compounded tirzepatide (produced by 503A or 503B compounding pharmacies, mostly in the form of tirzepatide base or a salt) is formulated differently from the Eli Lilly branded product. Some compounded preparations are reconstituted lyophilised powder rather than a ready-to-inject solution, and some are supplied in multi-dose vials containing bacteriostatic water or another antimicrobial-preservative-based diluent. If the labelling on a compounded vial explicitly states that it is a multi-dose container and specifies the in-use period, the handling rules for that container follow its own label, not the Eli Lilly single-dose vial instructions.

That is a meaningful distinction, but it does not resolve the dose-splitting question. Even if the receiving vial is a bacteriostatic-preserved multi-dose container, the source vial that supplies the residual drug still carries whatever contamination risk accumulated at first use. Transferring between vials is not a procedure described in any compounding pharmacy instructions for use we have reviewed. For specifics on bacteriostatic water and stability windows, see bacteriostatic water stability and storage for peptide reconstitution.

What to do instead

The titration schedule for tirzepatide starts at 2.5 mg weekly for four weeks and then moves to 5 mg. If a vial of one strength contains only enough drug for the earlier dose and not the later, the expected approach is to start a new vial at the higher dose strength rather than supplement from the old one. Eli Lilly supplies branded tirzepatide in dose-specific vials across the full titration range: 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL vial.

If cost or supply is driving the question, that is worth raising with a prescribing clinician. It is a known practical problem with injectable GLP-1 class medicines, and prescribers are aware that titration ladders can leave partial-use containers. The full titration ladder for tirzepatide runs from 2.5 mg to 15 mg weekly, and each step is supplied as a discrete dose-specific vial.

What we do not know yet

No published study, to our knowledge, has characterised the contamination risk specifically from tirzepatide vial-to-vial dose-splitting in home-use conditions. The absence of a peer-reviewed risk estimate is not a safety clearance. It means the practice is outside the scope of what was validated in clinical trials and what regulators reviewed when approving the product.

If you are using grey-market compounded tirzepatide, the handling rules that apply are whatever the compounding pharmacy specifies on the label, read alongside general injectable-safety principles. See the grey-market risks of tirzepatide for a fuller picture of what that supply chain looks like in practice.

This article is for educational purposes. If you are on a tirzepatide prescription, the specific question of whether and how to handle a partial vial belongs with the pharmacist or prescriber who dispensed it.